VRCA Q3 2024 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$2M-161.1% YoY

Gross Profit

-$2M124.4% margin

Operating Income

-$21M1162.5% margin

Net Income

-$23M1283.5% margin

EPS (Diluted)

$-4.88

QoQ Revenue Growth

-134.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$33M

Total Liabilities

$67M

Stockholders' Equity

-$34M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$2M	$3M	-161.1%
Gross Profit	-$2M	$3M	-179.9%
Operating Income	-$21M	-$24M	+13.4%
Net Income	-$23M	-$25M	+7.8%

Revenue Segments

Collaboration

$84,000100%